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A B S T R A C T
Background: Cancer is the leading cause of death in Korea. This study aims to examine changes in
temporal trends in major cancer mortality.
Materials and methods: Mortality data for 1993–2012 were obtained from the Korean Statistics Information
Service(KOSIS) database and age-standardized to the 2000 Korean population. Joinpoint analysis was used
to identify signiﬁcant changes in trends over time. The annual percentage rate change (APC) was
computed for each segment of the trends.
Results: The age-standardized mortality rates (ASR) for all cancer sites combined decreased by 9.1% and
1.1% in men and women, respectively, from 1983 to 2012. ASRs from cancers of esophagus, stomach, and
liver decreased substantially, whereas ASRs from cancer for all other sites increased markedly. ASRs for all
cancer sites combined increased until 1994 and thereafter decreased signiﬁcantly in both genders except
for the period of 1998–2002 (APC: 5.5% for men [p < 0.05] and 0.07% for women). ASRs for esophagus
and liver cancers increased until the early 1990s and thereafter declined, leading to signiﬁcant decreases
[p < 0.05] for esophagus cancer (APC: 1.85% for men and 3.82% for women) and liver cancer (APC:
1.55% for men and 0.56% for women) in 1983–2012. ASRs for stomach cancer declined (APC: 4.06%
for men and 4.07% for women) except for 1990–1994. ASRs for uterine cancer peaked in 2003 and then
declined (APC: 2.85%). ASRs increased signiﬁcantly until 2002 for colorectal cancer in men (APC: 7.52%)
and lung cancer in both genders. The most consistently upward trend was observed for non-Hodgkin’s
lymphoma (APC: 3.55% for men and 5.29% for women; number of joinpoints = 0). The greatest ASR
increase was seen for prostate cancer for which mortality increased until 2002 at an APC of 12.56%.
Conclusion: While mortality decreased signiﬁcantly for esophagus, stomach and liver cancers in recent
decades in Korea, challenges still remain for many other cancers, especially pancreatic, breast, and
prostate cancers and non-Hodgkin’s lymphoma. Surveillance of cancer mortality trends can lend valuable
insights as to the prevention and control of cancer. Public health promotion efforts to control cancer such
as lowering smoking rate and obesity could reduce the burden of cancer in many sites.
ã 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Cancer is a major public health problem in Korea as in many
other parts of the world [1]. The top three leading causes of death
in Korea in 2012 were heart diseases, cerebrovascular diseases, and
cancer, with cancer causing more deaths than heart and
cerebrovascular diseases combined [2]. Cancer has been the* Corresponding author. Fax: +82 43 710 0001.
E-mail addresses: moon5@kongju.ac.kr (D. Lim), minaha@dku.edu (M. Ha),
inmyungs@gmail.com (I. Song).
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1877-7821/ã 2015 The Authors. Published by Elsevier Ltd. This is an open access article unleading cause of death in Korea since 1983, and claimed
73,757 deaths in 2012, which accounted for one in three deaths
for men and one in four deaths for women [3]. A previous study
examined trends in cancer mortality in Korean men and women
who were of target age for the national cancer screening programs
using data for 1983–2007 (over 30 years for cervix, over 40 years
for stomach, liver, and breast, and over 50 years for colon and
rectum) [4]. Therefore, longer-term trends in cancer mortality in
the entire Korean population using data for three decades merit
investigation. This study aims to analyze temporal trends in major
cancer mortality rates in Korea from 1983 to 2012.der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2.1. Data
Mortality data for 1983–2012 were obtained from the Korean
Statistics Information Service (KOSIS) database [5]. The causes of
death in the KOSISdatabase were coded and classiﬁed according to
the International Classiﬁcation of Diseases, tenth revision(ICD-10)
codes. 13 major causes of cancer death were identiﬁed based on
2012 mortality statistics. The ICD-10 codes used for the causes of
cancer death were C15 for esophageal cancer, C16 for stomach
cancer, C18–C21 for colon and rectum cancer, C22 for liver cancer,
C25 for pancreatic cancer, C33–C34 for lung and bronchus (lung)
cancer, C50 for breast cancer, C53–C55 for uterine cancer, C61 for
prostate cancer, C67 for urinary bladder cancer, C71 for brain
cancer, C82–C85 for non-Hodgkin’s lymphoma, and C91–C95 for
leukemia. Overall cancer was deﬁned as cancer at any site (C00–
C97). Crude cancer mortality rates were computed and age-
standardized to account for the aging of the population using the
2010 Korean population as the standard population [6].
In Korea, the death certiﬁcate is mostly issued by a licensed
physician [7]. The immediate cause of death is a direct injury or
complication, and the underlying cause of death is the disease
having a medically causal relationship with the immediate cause of
death. For example, if a person dies with esophageal varix bleeding
complicated by liver cancer, the immediate cause of death is
esophageal varix bleeding and the underlying cause of death is
liver cancer.
2.2. Statistical analysis
We used joinpoint regression analysis to identify the years
when there were signiﬁcant changes in the age-standardized
mortality rates. Joinpoint regression analysis ﬁts a series of joined
straight lines to the age-standardized mortality rates on a
logarithmic scale [8]. Straight light segments are joined at
“joinpoints” where mortality trend changes its slope statistically
signiﬁcantly. The number of joinpoints started from 0 and was
increased to test if the addition of joinpoints improved the ﬁtness
of model signiﬁcantly. Analysis started with 0 and tested for model
ﬁt with a maximum of 5 joinpoints. The slope of each line segment
of the best-ﬁtting model was expressed as the annual percentage
rate change (APC) in the age-standardized mortality rate (ASR).Table 1
Crude and age-standardized death rates for major cancers in Korean men and women,
Men 
1983 2012 
Site Deathsa CDRb ASRc Deathsa CDRb ASRc ASR 
All sites 17,789 88.4 187.7 46,462 185.6 170.7 9.1 
Esophagus 559 2.8 6.4 1,278 5.1 4.7 26.
Stomach 7,566 37.6 83.5 6,090 24.3 22.4 73.
Colon & Rectum 340 17.0 3.6 4,692 18.7 17.6 371.4
Liver 4,801 23.9 48.6 8,494 33.9 34.0 30.
Pancreas 236 1.2 2.5 2,616 10.4 9.6 287.1
Lung 1,659 8.2 18.4 12,171 48.6 44.4 142.1
Breast – – – – – – – 
Uterine – – – – – – – 
Prostate 29 0.1 0.5 1,460 5.8 5.2 1053
Bladder 120 0.6 1.5 918 3.7 3.3 125.3
Brain 130 0.6 1.0 588 2.3 2.3 134.0
Non-Hodgkin’s lymphoma 139 0.7 1.2 927 3.7 3.8 221.8
Leukemia 489 2.4 2.5 919 3.7 3.5 38.1 
a Number of deaths.
b Crude death rates (per 100,000).
c Age-standardized death rates adjusted to the 2010 Korean standard population (pe
d Percentage of the 1983 rate.Signiﬁcance tests were performed using the Monte Carlo
permutation technique (two-sidedP < 0.05). The best-ﬁtting mod-
el was estimated separately for men and women. The Joinpoint
Regression Program version 4.1.0 (US National Cancer Institute,
Bethesda, MD, USA) was used for the statistical analysis. Approval
from the institutional review board was not required for this study.
3. Results
Table 1 describes the number of deaths, crude death rates, and
ASRs for major cancer sites in men and women in 1983–2012. The
overall cancer mortality rates for all sites combined decreased by
9.1% and 1.1% in men and women, respectively, from 1983 to 2012.
ASR % change, however, differed by site. ASRs from cancers of
esophagus, stomach, and liver decreased substantially, whereas
ASRs from cancer for all other sites increased markedly from
1983 to 2012. The highest increase in ASRs was observed for
prostate cancer at 1053.3%. Colorectal cancer, pancreatic cancer,
and non-Hodgkin’s lymphoma all had over 200% increases in ASRs
in both men and women. The lowest increase in ASRs was observed
for leukemia at 30% and 38.1% for women and men, respectively.
Tables 2 and 3 summarize the results of joinpoint analyses for
men and women, respectively. ASRs for all cancers sites combined
increased until 1994 and thereafter decreased signiﬁcantly in both
genders except for the period of 1998–2002 (APC: 5.5% for men
and 0.07% for women). In particular, ASRs from esophagus cancer
increased from 1983 to 1993 among men and thereafter decreased
signiﬁcantly. Similarly, ASRs from liver cancer also showed an
upward trend from 1983 to 1994 followed by signiﬁcant declines
except for the period of 1998–2002 (APC: 1.55% for men and
0.56% for women). ASRs from stomach cancer showed downward
trends from 1983 to 2012 except for 1991–1994 in men and for
1990–1993 in women. ASRs from colorectal cancer, on the other
hand, increased until 2002 in men and until 2004 in women and
leveled off (APC: 4.25% for men and 4.01% for women). ASRs from
pancreatic cancer also increased at a marked rate from 1983 to
1994 (APC until 1994: 9.82% for men and 12.57% for women), but
the rate of increase slowed thereafter. ASRs from lung cancer
increased at a rapid rate until 1993 in men and until 1994 in
women (APC: 9.83% for men and 8.98% for women) and then at a
slower rate until 2002 when they started to decrease.
ASRs from prostate cancer increased at an APC of 12.56% from
1983 to 2002 and thereafter leveled off. ASRs from breast cancer 1983–2012.
Women
1983 2012
% Changed Deathsa CDRb ASRc Deathsa CDRb ASRc ASR % Changed
10,998 55.6 102.78 27,297 109.3 101.7 1.1
8 121 0.6 1.19 120 0.5 0.4 63.0
2 4,579 23.1 45.32 3,252 13.0 12.1 73.3
 326 1.6 3.21 3,506 14.0 12.9 302.2
0 1,583 8.0 15.13 2,841 11.4 12.6 16.8
 160 0.8 1.61 2,162 8.7 8.0 398.1
 684 3.5 6.52 4,476 17.9 16.5 153.4
408 2.1 3.51 1,993 8.0 7.6 117.4
1421 7.2 12.4 1219 4.9 5.4 56.8
.3 – – – – – – –
 36 0.2 0.36 303 1.2 1.1 202.8
 84 0.4 0.6 545 2.2 2.3 314.3
 75 0.4 0.6 598 2.4 2.7 339.3
428 2.2 2.20 747 3.0 2.9 30.0
r 100,000).
Table 2
Trends in age-standardized death rates for major cancers in Korean men according to joinpoint analysis, 1983–2012a.
Trend 1 Trend 2 Trend 3 Trend 4 Trend 5
APC 1983–2012 Period APC Period APC Period APC Period APC Period APC
All sites 0.55b 1983–1991 2.00b 1991–1994 4.54b 1994–1998 2.78b 1998–2002 1.00 2002–2012 3.06b
Esophagus 1.85b 1983–1993 4.14b 1993–2002 2.34b 2002–2012 5.12b
Stomach 4.06b 1983–1991 3.43b 1991–1994 1.52 1994–1998 6.90b 1998–2002 1.97b 2002–2012 6.56b
Colon & Rectum 4.25b 1983–2002 7.52b 2002–2012 0.16
Liver 1.55b 1983–1994 1.54b 1994–1998 5.46b 1998–2002 1.11 2002–2012 3.52b
Pancreas 2.04b 1983–1994 9.82b 1994–2012 0.21
Lung 1.37b 1983–1993 9.83b 1993–2002 1.82b 2002–2012 2.40b
Prostate 6.28b 1983–2002 12.56b 2002–2012 0.56
Bladder 1.32b 1983–1995 6.44b 1995–1998 4.68 1998–2002 10.43b 2002–2005 8.34 2005–2012 1.49
Brain 0.26 1983–1988 38.67b 1988–2012 0.98b
Non-Hodgkin’s lymphoma 3.55b 1983–2012 3.55b
Leukemia 0.51b 1983–1993 4.86b 1993–2012 0.78b
a APC annual percent rate change of age-standardized death rates.
b The annual percent rate change is signiﬁcantly different from 0 (two-sided p < 0.05).
Table 3
Trends in age-standardized death rates for major cancers in Korean women according to joinpoint analysis, 1983–2012a.
Trend 1 Trend 2 Trend 3 Trend 4 Trend 5
APC 1983–2012 Period APC Period APC Period APC Period APC Period APC
All sites 0.07 1983–1991 1.06b 1991–1994 6.18b 1994–1998 2.66b 1998–2002 +2.16 2002–2012 2.12b
Esophagus 3.82b 1983–1995 0.71 1995–2012 6.30b
Stomach 4.07b 1983–1990 5.11b 1990–1993 4.37b 1993–1998 6.34b 1998–2002 2.83b 2002–2012 6.13b
Colon & Rectum 4.01b 1983–1994 10.24b 1994–2004 5.04b 2004–2012 1.09b
Liver 0.56b 1983–1994 1.50b 1994–1999 4.13b 1999–2002 7.17b 2002–2012 2.98b
Pancreas 3.51b 1983–1994 12.57b 1994–2012 1.71b
Lung 2.22b 1983–1994 8.98b 1994–2002 2.54b 2002–2012 1.27b
Breast 2.74b 1983–1990 2.85b 1990–1993 8.24 1993–2005 2.53b 2005–2012 0.98
Uterine 2.43b 1983–2003 1.80b 2003–2012 4.47b
Bladder 2.42b 1983–1993 10.74b 1993–1998 1.13 1998–2001 13.06 2001–2012 2.08b
Brain 1.49b 1983–1989 33.26b 1989–2012 0.08
Non-Hodgkin’s lymphoma 5.29b 1983–2012 5.29b
Leukemia 0.34 1983–1993 3.95b 1993–2012 0.75b
a APC annual percent rate change of age-standardized death rates.
b The annual percent rate change is signiﬁcantly different from 0 (two-sided p < 0.05).
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After a peak in 2003, uterine cancer mortality started its downward
trend (APC: 5.66% in 2003–2012). ASRs from urinary bladder
cancer ﬂuctuated periodically, showing an M-shaped temporal
pattern (Fig. 1). ASRs from brain cancer increased at a high rate in
1983–1988 in men and in 1983–1989 in women (APC: 38.35% and
32.76%, respectively) and thereafter declined. No joinpoint was
identiﬁed for ASRs from non-Hodgkin’s lymphoma (APC: 3.55% for
men and 5.29% for women). ASRs from leukemia increased from
1983 to 1993 in both genders (APC: 4.86% for men and 3.95% for
women) and thereafter declined.
4. Discussion
Overall, cancer mortality rates in Korea peaked in 1994 and
thereafter decreased by 2–3% per year in both genders except for
the period of 1998–2002. The decreases in mortality rates from
cancers of esophagus, stomach, and liver drove the overall decrease
in cancer mortality rates. The downward trend in overall cancer
mortality may be partly attributable to the overarching efforts of
the Korean government to improve cancer screening and control
[9]. Regular screening of cervical cancer in Korea was shown to
reduce the incidence of invasive cervical cancer [10]. The
government initiated a comprehensive ‘10-year Plan for Cancer
Control’ in 1996, launched the National Cancer Screening Program
(NCSP) in 1999, and legislated the Cancer Control Act in 2003. NCSP
was initially intended to provide Medical Aid beneﬁciaries withfree screening for stomach, breast, and cervical cancers. The
coverage of the program has been gradually expanded; now in
addition to Medical Aid recipients, the National Health Insurance
enrollees within the lower 50% premium group receive free cancer
screening for ﬁve cancer sites (the stomach, liver, colorectum,
breast, and uterine cervix) exempted from a 20% out-of-pocket
payment (Table S1).
While the Korean government’s effort to improve cancer
screening can have a more immediate impact on cancer mortality,
changes in major life style factors such as diet, physical activity, and
smoking can inﬂuence the occurrence of many cancers and thereby
mortality although the direction of the impact can vary by type of
cancer. Taken together, men experienced a steeper downward
trend in cancer mortality rates compared with women. This is
partly due to the decreases in mortality rates from esophagus, liver,
and lung cancers, which traditionally affected men at a higher rate
than women [11]. The downward trend in esophagus cancer
mortality rate in Korea since 1994, particularly in men, may be
related to a reduced prevalence of major risk factors for esophagus
cancer such as smoking [12,13]. The rate of Korean men who smoke
has signiﬁcantly decreased in recent decades, partly due to the
government’s implementation of anti-smoking programs in
1995 as part of the National Health Promotion Act [11].
While stomach cancer has been the most commonly diagnosed
cancer in Korea [14], the mortality rate has been declining since
1983 except for a brief period in the early 1990s. This is consistent
with the worldwide trend of declining stomach cancer mortality
Fig. 1. Trends in age-standardized death rates for major cancers in Korea, 1983–2012.
Rates are age-adjusted to the 2010 Korean standard population.
942 D. Lim et al. / Cancer Epidemiology 39 (2015) 939–946[15,16]. The downward trends were associated with socioeconomic
improvements [17], a decrease in the intake of salty foods and
nitrate, and the reduction of Helicobacter pyloriinfections in Korea
[18–20]. In addition, the stable trend in the incidence rate of
stomach cancer in Korea suggests that early diagnosis and
treatment due to a higher rate of stomach cancer screenings
might have contributed to the decrease in stomach cancermortality [9,21]. The favorable mortality trends notwithstanding,
stomach cancer remained the second leading cause of cancer death
worldwide in 2008 [1], and the third and fourth most common
cause of cancer death for Korean men and women, respectively, in
2012.
The downward trend in stomach cancer mortality was
accompanied by an upward trend in colorectal cancer mortality.
Fig. 1. (Continued)
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had the second biggest increase in ASRs from 1983 to 2012, mostly
due to the increases until the early 2000s. The upward trends in
colorectal cancer incidence and mortality may be linked to factors
such as the adoption of Western diets, excess body weights, and
physical inactivity [22,23]. However, colorectal cancer mortality
leveled off over the last decade in our analysis. Similar trends in
colorectal cancer mortality of steady increases followed by
leveling-off were observed in Europe [24]. The recent downward
trends in colorectal cancer mortality in the European Union were
attributed to improvements in early diagnosis and treatment [25].
Performing colonoscopy in usual practice was associated with
fewer deaths from colorectal cancer [26]. The steady increase in
the incidence rate for colorectal cancer in Korea in the 2000s [27]
also suggests that the recent downward mortality trend might be
attributable to the wider use of colorectal cancer screening.
Liver cancer mortality increased signiﬁcantly until 1994 and
thereafter decreased except between 1998 and 2002. With
treatments largely ineffective, liver cancer mortality isapproximately the same as its incidence, highlighting the
importance of prevention of liver cancer. While there were
substantial variations in primary liver cancer mortality rates and
temporal trends across countries [28], the incidence rates of liver
cancer decreased in Asian countries in recent decades, which
traditionally had higher rates than the other parts of the world
[29]. Globally, 78% of hepatocellular carcinoma was attributable to
hepatitis B and hepatitis C virus infections (53% and 25%,
respectively) [30]. The decreases in the incidence rates of primary
liver cancer in developing countries were ascribed to the decreased
seroprevalence of hepatitis B virus [31]. The downward trend in
liver cancer mortality in Korea may also reﬂect the increasing
number of people who get hepatitis B vaccinations [32]. Despite
the remarkable reduction in liver cancer mortality rates over the
last three decades, however, liver cancer remained the second
most common cause of cancer death among Korean men in 2012.
Similar to liver cancer, ASRs from pancreatic cancer in Korea
increased markedly until 1994, contributing to the highest and the
third highest ASR % change between 1983 and 2012 for women and
944 D. Lim et al. / Cancer Epidemiology 39 (2015) 939–946men, respectively. Since 1994, however, pancreatic cancer mortal-
ity leveled off. Pancreatic cancer mortality rates also decreased in
the United States [33], and leveled off in most European countries
and Japan [34,35]. With the incidence rate being approximately
equal to the mortality rate for pancreatic cancer, the leveling-off of
pancreatic cancer mortality in recent decades reﬂects a stabilizing
trend in the incidence rate of pancreatic cancer: the age-
standardized incidence rate of pancreatic cancer in Korea have
reached a plateau in 2005 [21]. The leveling-off of pancreatic
cancer mortality rates, especially among Korean men, may be
related to the downward trend in smoking rates, a known risk
factor for pancreatic cancer, in recent decades [11,13,36].
Lung cancer was the most commonly diagnosed cancer and the
most common cause of cancer death worldwide in 2008 [1].
Likewise, ASRs for lung cancer in Korea more than doubled from
1983 to 2012 in both genders, making lung cancer the leading
cause of cancer death in 2012. Joinpoint analysis revealed that lung
cancer mortality in Korea increased to a peak in 2002 and
thereafter leveled off in both genders. A slightly different pattern
between genders emerged in many European countries: lung
cancer mortality showed signs of leveling off in recent decades
among men, but the upward trend persisted among women [37–
39], suggesting that smoking rates between the two genders are
converging. No major improvements occurred in lung cancer
treatment, so it is likely that various anti-smoking programs and
policies may have contributed to the recent favorable trend in lung
cancer mortality in Korea [11].
Breast cancer was the most common cause of cancer death
among women in the world in 2008 [1]. Our analysis showed that
ASRs from breast cancer in Korea increased until 2005. Breast
cancer mortality has steadily declined in the last three decades in
many European countries [40,41]. In developing countries,
however, breast cancer mortality rates rose in the 1970s and
1980s [42]. Korea had the highest rate of increase in breast cancer
mortality rate among Asian countries [43]. Korea in the past was
one of the countries with the lowest breast cancer incidence and
mortality rates in the world [42]. It appears, however, that the
country experienced the increasing breast cancer mortality due to
its economic development, lifestyle changes including delayed age
of marriage and child birth, and early menarche [44]. The leveling-
off of breast cancer mortality since 2005 may be ascribed to
improvements in early detection and treatment of breast cancer
[43].
Unlike for breast cancer, economic development appears to lead
to a reduction in cervical cancer rates [45]. In Korea, whose
economy witnessed remarkable progress in recent decades,
uterine cervix cancer mortality rates showed the signiﬁcant and
persistent downward trend since 2003. The association between
economy and cervical cancer mortality can also be inferred from
the diverging trends in cervical cancer mortality between the
developed member countries and the less developed counterparts
of the European Union [46]. In addition to economic development,
increasing screening for cervical cancer in Korea might have
contributed to the downward trend in cervical cancer mortality
which is largely preventable with early screening and treatment
[9,10]. Nationwide screening programs for cervical cancer in other
developed countries also were shown to have contributed to the
favorable trends in cervical cancer mortality [47,48].
The most alarming trend was observed for prostate cancer
mortality. Prostate cancer, which was an insigniﬁcant cause of
death at the beginning of the study period, became the 6th leading
cause of cancer death in 2012, as a result of the dramatic increase in
the mortality in 1983–2002. The steep increase during this period
might be attributable to an increase in obesity, consumption of
dietary fat and physical inactivity that resulted from economic
development [49]. Further economic development, however,appears to have a positive effect on reducing prostate cancer
mortality: it has been increasing in developing countries but
decreasing in more afﬂuent countries [49–51]. The leveling-off of
prostate cancer mortality rate in Korea since 2002 might also
reﬂect improvements in early detection and management of the
cancer [52,53].
Although they ﬂuctuated periodically, ASRs from urinary
bladder cancer declined since the early 2000s. Mortality from
bladder cancer has declined in most western European countries
over the last two decades [53,54]. The recent favorable trend in
bladder cancer mortality in Korean men might reﬂect the declines
in their smoking rate as cigarette smoking is a major risk factor for
urinary bladder cancer [55]. However, it is not likely that smoking
played a role in decreasing mortality trend in women as their
smoking rate increased in recent decades [11]. The declining
mortality in women might be partly due to improved control of
urinary tract infections, although their role in bladder cancer
remains unclear [53].
Brain cancer mortality increased by over 30% per year until
1988–1989 and thereafter stabilized although it tends to vary from
year to year. Also, in the United States [56] and the Nordic countries
[57], brain cancer mortality started declining or stabilized in the
early 1980s. Brain and central nervous system cancers consist of a
heterogeneous group of histological types [57], and little is known
about the factors responsible for the majority of primary brain
cancers [58]. Therefore, what might have caused the extraordinary
change in trends in Korea around 1988–1989 is hard to speculate,
but we cannot rule out the increase of early diagnosis and
treatment due to rapid adoption of brain imaging technology,
particularly computed tomography, in the country [59]. In
addition, improved survival rates for brain cancer, particularly
among younger patients, might have played a role, as observed in
Western countries from the early 1970s [57,58].
Non-Hodgkin’s lymphoma displayed the most consistent
increase in mortality rates through the study period. Similar
upward trends in non-Hodgkin’s lymphoma mortality were
observed in the United States, the European Union and Japan
until the 1990s [60]. However, the mortality rates in the United
States declined at a rate of 3% in the 2000s [52]. The etiologies and
risk factors of most non-Hodgkin’s lymphomas as well as the
reasons for the upward trend remain poorly understood [61].
Neither changes in classiﬁcation systems nor improved diagnostic
capabilities could fully explain the upward trend in the incidence
rate of non-Hodgkin’s lymphoma [62]. This trend warrants further
investigation.
Leukemia is a heterogeneous group of hematopoietic malig-
nancies and the etiology for some subtypes such as acute myeloid
leukemia remains unclear [63]. After a decade of increases,
leukemia mortality in Korea started decreasing since 1993 reﬂect-
ing improvements in the treatment of some subtypes. Downward
trends in leukemia mortality in some European countries were
ascribed to the fact that some subtypes, such as acute lympho-
blastic leukemia of childhood, were amenable to treatment [64].
Similarly in the United States, the survival rates from leukemia
improved markedly in the past three decades, and mortality from
chronic myeloid leukemia declined at an annual rate of 8.4% in the
2000s [52].
We presented a comprehensive overview of trends in mortality
from major cancers since 1983 in Korea. Until recently, Korea
resembled the cancer mortality trends in developing countries that
were predominated by the cancer types that were related to viral
and bacterial infections, such as stomach, liver and uterine cervix
cancers. While mortality from those cancers decreased in recent
decades, Korea also experienced upwards trends in smoking-
related cancers such as lung and urinary bladder cancers, as well as
D. Lim et al. / Cancer Epidemiology 39 (2015) 939–946 945many other cancers for which their etiology was not fully
understood.
While mortality trends can provide important insights into
potential changes in the risk factors as well as improvements in
early detection and treatment, they can also reﬂect underlying
changes in diagnostic classiﬁcation. Therefore, the following
limitations should be considered when interpreting the results
of this study because changes in mortality trends might reﬂect
changes in documentation and diagnostic coding rather than real
changes in survival. First, the observed trends in mortality may
have been inﬂuenced by potential misclassiﬁcation of causes of
death in ofﬁcial death certiﬁcates. The agreement rate between
death certiﬁcates and medical charts for malignant neoplasms was
80.4% in a regional district in Korea in 1998 [65]. Second, as one
possible cause of misclassiﬁcation is diagnostic errors, the
changing temporal trends, particularly the upward trends, may
reﬂect, to some extent, improved diagnostic techniques over time.
It is likely that the accuracy of causes of death on death certiﬁcates
may have evolved over time due to advances in diagnostic
techniques, thereby making mortality data incomparable between
different time periods. Third, the observed trends in mortality in
Korea may have been affected by change of codling scheme
application: the ICD-9 coding scheme in KOSIS data was replaced
with the ICD-10 in 1995.
In conclusion, trends in major cancer mortality in Korea showed
signiﬁcant changes in recent decades and the changes varied by
cancer site. While mortality decreased signiﬁcantly for cancers of
esophagus, stomach and liver, challenges still remain for many
cancers, especially, pancreatic, breast and prostate cancers, and
non-Hodgkin’s lymphoma. This study highlights the importance of
using cancer surveillance data to assist the development of cancer
control plans. Public health promotion efforts to control cancer
such as lowering smoking rate and obesity could reduce the burden
of cancer in many sites.
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